Panacea Biotec Secures $4.75M Vaccine Supply Deal with PAHO
Filing Summary
Panacea Biotec Ltd has received an award notification from the Pan American Health Organization (PAHO) for the supply of its Easyfive-TT vaccine. The agreement, valued at approximately US$ 4.75 million, covers the calendar years 2026 and 2027. This contract involves the supply of the Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) vaccine. The agreement is executed under a long-term arrangement with PAHO, an international entity. This transaction is not classified as a related party transaction.
Panacea Biotec Ltd has announced the receipt of an award notification from the Pan American Health Organization (PAHO) for the supply of its Easyfive-TT vaccine. The agreement is valued at approximately US$ 4.75 million and covers the supply period for calendar years 2026 and 2027. The vaccine in question is the Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) vaccine, also known as Easyfive-TT.
The agreement with PAHO is structured as a long-term arrangement, valid until December 31, 2027. The contract specifies the supply of the Easyfive-TT vaccine in a liquid, single-dose format. This transaction is categorized under an international order, with PAHO being the awarding entity. The agreement does not involve any related party transactions, and there is no interest from the promoter or promoter group in the awarding entity.
PAHO, the regional office of the World Health Organization, focuses on improving health and living standards in the Americas. It collaborates with various countries to combat diseases and promote health initiatives. The organization plays a significant role in vaccine distribution and health policy implementation across the region.
Panacea Biotec Ltd is a biotechnology company engaged in the research, development, and manufacturing of vaccines and pharmaceutical formulations. The company prioritizes innovation in healthcare solutions and has a portfolio that includes vaccines for various infectious diseases. Panacea Biotec continues to focus on expanding its global reach through strategic partnerships and agreements.